Psychophysical aspects of hidradenitis suppurativa
- PMID: 20526543
- DOI: 10.2340/00015555-0866
Psychophysical aspects of hidradenitis suppurativa
Abstract
Hidradenitis suppurativa is a recurrent, debilitating suppurative skin disease. The symptoms are much more than just physical, but studies of its impact on patients' psychological state and related quality of life are very limited. The current study was conducted with a group of 54 patients, aged 16-65 years, who had an active, but stable, course of hidradenitis suppurativa. The aim of the study was to determine the influence of hidradenitis suppurativa on a broad spectrum of psychophysical factors. Assessment was carried out using several questionnaires, which revealed the following mean scores: Dermatology Life Quality Index (DLQI) (12.67 +/- 7.7), Beck Depression Inventory-Short Form (BDI-SF) (5.87 +/- 4.68), Evers et al. "6-Item Scale" (3.87 +/- 3.65), EQ-5D (0.66 +/- 0.23 (health index) and 56.78 +/- 18.84 (VAS)), Functional Assessment of Chronic Illness Therapy - Fatigue scale (FACIT-F) (32.06 +/- 11.01) and Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) (56.44 +/- 15.17%). The results highlight the important impact of hidradenitis suppurativa on a wide spectrum of psychophysical aspects and impairment of related quality of life among patients. Our findings indicate that advancement of the disease seems to be the most important factor negatively influencing patients' well-being (p < 0.01). It is noteworthy that an anogenital location appears to impair the hidradenitis suppurativa patients' quality of life most of all (p < 0.05), but the occurrence of lesions on uncovered skin plays a crucial role in the stigmatization level (p < 0.05).
Similar articles
-
Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity.Br J Dermatol. 2009 Oct;161(4):831-9. doi: 10.1111/j.1365-2133.2009.09198.x. Epub 2009 Apr 29. Br J Dermatol. 2009. PMID: 19438453
-
Quality of life impairment in hidradenitis suppurativa: a study of 61 cases.J Am Acad Dermatol. 2007 Apr;56(4):621-3. doi: 10.1016/j.jaad.2006.08.061. Epub 2006 Oct 20. J Am Acad Dermatol. 2007. PMID: 17097366
-
Psychosocial impact of hidradenitis suppurativa: a qualitative study.Acta Derm Venereol. 2011 May;91(3):328-32. doi: 10.2340/00015555-1082. Acta Derm Venereol. 2011. PMID: 21394419
-
[Treatment options in severe hidradenitis suppurativa].Ned Tijdschr Geneeskd. 2011;155:A1912. Ned Tijdschr Geneeskd. 2011. PMID: 21426594 Review. Dutch.
-
The Handicap of Hidradenitis Suppurativa.Dermatol Clin. 2016 Jan;34(1):17-22. doi: 10.1016/j.det.2015.07.003. Epub 2015 Sep 14. Dermatol Clin. 2016. PMID: 26617353 Review.
Cited by
-
Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): protocol for a prospective cohort study.BMJ Open. 2022 Apr 21;12(4):e060815. doi: 10.1136/bmjopen-2022-060815. BMJ Open. 2022. PMID: 35450918 Free PMC article.
-
Perspectives On Perceived Stigma And Self-Stigma In Patients With Hidradenitis Suppurativa.Clin Cosmet Investig Dermatol. 2019 Oct 16;12:785-790. doi: 10.2147/CCID.S180036. eCollection 2019. Clin Cosmet Investig Dermatol. 2019. PMID: 31802927 Free PMC article. Review.
-
Misfortunes never come singly but in fours - follicular occlusion tetrad.Postepy Dermatol Alergol. 2024 Apr;41(2):245-249. doi: 10.5114/ada.2024.138652. Epub 2024 Apr 9. Postepy Dermatol Alergol. 2024. PMID: 38784934 Free PMC article. No abstract available.
-
Proceeding report of the third symposium on Hidradenitis Suppurativa advances (SHSA) 2018.Exp Dermatol. 2019 Jul;28(7):769-775. doi: 10.1111/exd.13928. Epub 2019 Apr 29. Exp Dermatol. 2019. PMID: 30924968 Free PMC article.
-
Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study.Br J Dermatol. 2021 Jul;185(1):177-184. doi: 10.1111/bjd.19863. Epub 2021 May 4. Br J Dermatol. 2021. PMID: 33544917 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical